You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
|
|---|---|
| Published in |
BMC Neurology, June 2012
|
| DOI | 10.1186/1471-2377-12-36 |
| Pubmed ID | |
| Authors |
Patrick Vermersch, Rabah Benrabah, Nicolas Schmidt, Hélène Zéphir, Pierre Clavelou, Cyrille Vongsouthi, Patrice Dubreuil, Alain Moussy, Olivier Hermine |
| Abstract |
Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because they release large amounts of various mediators that sustain the inflammatory network. Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and activity of mast cells. This exploratory study assessed the safety and clinical benefit of masitinib in the treatment of primary progressive MS (PPMS) or relapse-free secondary progressive MS (rfSPMS). |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 20% |
| Egypt | 1 | 20% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 136 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 1% |
| Spain | 1 | <1% |
| France | 1 | <1% |
| South Africa | 1 | <1% |
| Unknown | 131 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 15% |
| Student > Ph. D. Student | 19 | 14% |
| Unspecified | 12 | 9% |
| Student > Bachelor | 12 | 9% |
| Student > Master | 9 | 7% |
| Other | 38 | 28% |
| Unknown | 25 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 26% |
| Neuroscience | 14 | 10% |
| Unspecified | 12 | 9% |
| Agricultural and Biological Sciences | 11 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
| Other | 25 | 18% |
| Unknown | 32 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 43. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 February 2022.
All research outputs
#845,616
of 23,202,641 outputs
Outputs from BMC Neurology
#42
of 2,482 outputs
Outputs of similar age
#4,618
of 168,140 outputs
Outputs of similar age from BMC Neurology
#1
of 38 outputs
Altmetric has tracked 23,202,641 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,482 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,140 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.